2071 Results

People

  1. Hudis
    Hudis
  2. Norton
    Norton
  3. Zelenetz
    Zelenetz
  4. Yahalom
    Yahalom
  5. Cheung
    Cheung
  6. O'Reilly
    O'Reilly
  7. Kushner
    Kushner
  8. Perales
    Perales
  9. La Quaglia
    La Quaglia
  10. Giralt
    Giralt

Groups

  1. Department of Medicine (1047)
  2. Center for Hematologic Malignancies (589)
  3. Hematologic Malignancies, Division of (537)
  4. Survivorship Research (532)
  5. Solid Tumor Oncology Division (487)
  6. Pediatrics, Department of (383)
  7. Surgery (287)
  8. GSK Faculty (276)
  9. Breast Medicine Service (255)
  10. Tow Center for Developmental Oncology (TCDO) (240)
  1. "cyclophosphamide"
Formats
  1. Journal Article (1932)
  2. Review (52)
  3. Conference Paper (46)
  4. Editorial (11)
  5. Research Letter (11)
  6. Meeting Abstract (8)
  7. Correspondence (6)
  8. Guidelines (4)
  9. Book Section (1)
Groups
  1. Department of Medicine (1047)
  2. Center for Hematologic Malignancies (589)
  3. Hematologic Malignancies, Division of (537)
  4. Survivorship Research (532)
  5. Solid Tumor Oncology Division (487)
  6. Pediatrics, Department of (383)

More Groups

People
  1. Clifford Hudis (130)
  2. Larry Norton (104)
  3. Andrew Zelenetz (75)
  4. Joachim Yahalom (72)
  5. Nai-Kong Cheung (71)
  6. Richard O'Reilly (67)

More People

Years
  1. 2025 (45)
  2. 2024 (86)
  3. 2023 (56)
  4. 2022 (44)
  5. 2021 (23)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (155)
  2. Cancer (109)
  3. Blood (81)
  4. Leukemia and Lymphoma (50)
  5. Biology of Blood and Marrow Transplantation (49)
  6. Bone Marrow Transplantation (48)

More Publications

Publishers
  1. Elsevier Inc. (345)
  2. American Society of Clinical Oncology (163)
  3. Wiley Blackwell (150)
  4. Springer (147)
  5. American Society of Hematology (113)
  6. Lippincott Williams & Wilkins (112)

More Publishers

Results (2071)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: The phase II GATHER study
    Journal Article

    Sharman, J. P.; Forero-Torres, A.; Costa, L. J.; Flinn, I. W.; Inhorn, L.; Kelly, K.; Bessudo, A.; Fayad, L. E.; Kaminski, M. S.; Evens, A. M.; more...
    Leukemia and Lymphoma (2019)

    Fulltext@MSK | Save
  • Summary of the second annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
    Review

    Holstein, S. A.; Ye, J. C.; Howard, A.; Bhutani, M.; Gormley, N.; Hahn, T.; Hillengass, J.; Krishnan, A.; Landgren, C. O.; Munshi, N. C.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Phf6 loss enhances HSC self-renewal driving tumor initiation and leukemia stem cell activity in T-ALL
    Journal Article

    Wendorff, A. A.; Quinn, S. A.; Rashkovan, M.; Madubata, C. J.; Ambesi-Impiombato, A.; Litzow, M. R.; Tallman, M. S.; Paietta, E.; Paganin, M.; Basso, G.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Permanent chemotherapy-induced alopecia in patients with breast cancer: A 3-year prospective cohort study
    Journal Article

    Kang, D.; Kim, I. R.; Choi, E. K.; Im, Y. H.; Park, Y. H.; Ahn, J. S.; Lee, J. E.; Nam, S. J.; Lee, H. K.; Park, J. H.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: A randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
    Journal Article

    Bolaños-Meade, J.; Reshef, R.; Fraser, R.; Fei, M.; Abhyankar, S.; Al-Kadhimi, Z.; Alousi, A. M.; Antin, J. H.; Arai, S.; Bickett, K.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial - Clinical outcomes and molecular determinants of response
    Journal Article

    Murphy, C.; Muscat, A.; Ashley, D.; Mukaro, V.; West, L.; Liao, Y.; Chisanga, D.; Shi, W.; Collins, I.; Baron-Hay, S.; more...
    PLoS ONE (2019)

    Fulltext@MSK | Save
  • Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
    Journal Article

    Jin, C. H.; Xia, J.; Rafiq, S.; Huang, X.; Hu, Z.; Zhou, X.; Brentjens, R. J.; Yang, Y. G.
    EBioMedicine (2019)

    Fulltext@MSK | Save
  • Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: A report from the Childhood Cancer Survivor Study cohort
    Journal Article

    Gibson, T. M.; Mostoufi-Moab, S.; Stratton, K. L.; Leisenring, W. M.; Barnea, D.; Chow, E. J.; Donaldson, S. S.; Howell, R. M.; Hudson, M. M.; Mahajan, A.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Early fluid overload is associated with an increased risk of nonrelapse mortality after ex vivo CD34-selected allogeneic hematopoietic cell transplantation
    Journal Article

    Rondon-Clavo, C.; Scordo, M.; Hilden, P.; Shah, G. L.; Cho, C.; Maloy, M. A.; Papadopoulos, E. B.; Jakubowski, A. A.; O'Reilly, R. J.; Gyurkocza, B.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance
    Journal Article

    Boyiadzis, M. M.; Dhodapkar, M. V.; Brentjens, R. J.; Kochenderfer, J. N.; Neelapu, S. S.; Maus, M. V.; Porter, D. L.; Maloney, D. G.; Grupp, S. A.; Mackall, C. L.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save